Zheng Ying-Ying, Gao Ying, Chen You, Wu Ting-Ting, Ma Yi-Tong, Zhang Jin-Ying, Xie Xiang
Zhengzhou University First Affiliated Hospital Department of Cardiology Zhengzhou People's Republic of China Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Xinjiang Medical University First Affiliated Hospital Department of Cadre Ward Urumqi Xinjiang People's Republic of China Department of Cadre Ward, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China.
Braz J Cardiovasc Surg. 2019 Dec 1;34(6):645-652. doi: 10.21470/1678-9741-2018-0176.
To perform a systematic review and meta-analysis of studies comparing coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), and medical treatment (MT) in patients with chronic total occlusions (CTOs).
We identified eligible observational studies published in the China National Knowledge Infrastructure database, PubMed, Excerpta Medica database, Google Scholar, Cochrane Library, Web of Science, and "Clinical trials" registration from 1999 to October 2018. Main outcome measures were all-cause mortality, cardiac death, major adverse cardiac events (MACEs), and myocardial infarction (MI).
There were eight observational studies including 6985 patients. Patients' mean age was 64.4 years. Mean follow-up time was 4.3 years. Comparing with MT (2958 patients), PCI (3157 patients) presented decreased all-cause mortality (odd ratio [OR]: 0.46, 95% confidence interval [CI]: 0.36-0.60; P<0.001), cardiac death (OR: 0.40, 95% CI: 0.31-0.52; P<0.001), MACE (OR: 0.55, 95% CI: 0.43-0.71; P<0.001), and MI (OR: 0.40, 95% CI: 0.26-0.62; P<0.001). Comparing with MT, CABG (613 patients) presented lower all-cause mortality (OR: 0.50, 95% CI: 0.36-0.69; P<0.001) and MACE (OR: 0.50, 95% CI: 0.26-0.96; P=0.04), but not lower MI (OR: 0.23, 95% CI: 0.03-1.54; P=0.13) and cardiac death (OR: 0.83, 95% CI: 0.51-1.35). Comparing with CABG, PCI did not present decreased risk for those outcomes.
PCI or CABG was associated with better clinical outcome in patients with CTO than MT. PCI is not better than CABG in decreasing mortality, MI, cardiac death, and MACE in coronary CTO patients.
对比较慢性完全闭塞病变(CTO)患者冠状动脉旁路移植术(CABG)、经皮冠状动脉介入治疗(PCI)和药物治疗(MT)的研究进行系统评价和荟萃分析。
我们在中国知网数据库、PubMed、医学文摘数据库、谷歌学术、Cochrane图书馆、科学引文索引数据库以及“临床试验”注册库中检索了1999年至2018年10月发表的符合条件的观察性研究。主要结局指标为全因死亡率、心源性死亡、主要不良心血管事件(MACE)和心肌梗死(MI)。
共有8项观察性研究,纳入6985例患者。患者平均年龄为64.4岁。平均随访时间为4.3年。与MT组(2958例患者)相比,PCI组(3157例患者)的全因死亡率(比值比[OR]:0.46,95%置信区间[CI]:0.36 - 0.60;P < 0.001)、心源性死亡(OR:0.40,95% CI:0.31 - 0.52;P < 0.001)、MACE(OR:0.55,95% CI:0.43 - 0.71;P < 0.001)和MI(OR:0.40,95% CI:0.26 - 0.62;P < 0.001)均降低。与MT组相比,CABG组(613例患者)的全因死亡率(OR:0.50,95% CI:0.36 - 0.69;P < 0.001)和MACE(OR:0.50,95% CI:0.26 - 0.96;P = 0.04)较低,但MI(OR:0.23,95% CI:0.03 - 1.54;P = 0.13)和心源性死亡(OR:0.83,95% CI:0.51 - 1.35)未降低。与CABG组相比,PCI组在这些结局方面的风险并未降低。
对于CTO患者,PCI或CABG的临床结局优于MT。在降低冠状动脉CTO患者的死亡率、MI、心源性死亡和MACE方面,PCI并不优于CABG。